Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00451516
Status:
COMPLETED
Last Update Posted:
2008-05-19
First Post:
2007-03-22
Brief Title:
St Johns Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety
Sponsor:
The University of Queensland
Organization:
The University of Queensland
Study Overview
Official Title:
St Johns Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety
Status:
COMPLETED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
SJW has the greatest evidence of herbal medicine efficacy in treating MDD In treating anxiety kava has the greatest evidence of efficacy As comorbidity of MDD and anxiety commonly occurs it is conceivable that a combination of an established antidepressant agent such as SJW and an established anxiolytic agent such as kava may effectively treat MDD presenting with comorbid anxiety It is possible that a beneficial synergistic effect may also occur between SJW and kava improving the treatment outcomes in MDD with comorbid anxiety than by the individual substances alone Determination of this is not addressed in this study due to limitations of time and resources The determination of the strength of the SJW-kava combination will be ascertained by comparing similar trials using SJW and kava mono-therapy in addressing MDD and GAD
The hypothesis is that a combination of SJW and kava will reduce MDD occurring with comorbid anxiety more than placebo
The hypothesis is that a combination of SJW and kava will reduce MDD occurring with comorbid anxiety more than placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None